- TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Herbst, R.S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B.E., Sandler, A., Kris, M.G., Tran, H.T., Klein, P., Li, X., Ramies, D., Johnson, D.H., Miller, V.A. J. Clin. Oncol. (2005)